CN1137684C - 用碱性试剂稳定的药物组合物 - Google Patents

用碱性试剂稳定的药物组合物 Download PDF

Info

Publication number
CN1137684C
CN1137684C CNB961920653A CN96192065A CN1137684C CN 1137684 C CN1137684 C CN 1137684C CN B961920653 A CNB961920653 A CN B961920653A CN 96192065 A CN96192065 A CN 96192065A CN 1137684 C CN1137684 C CN 1137684C
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition according
suspension
salt
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB961920653A
Other languages
English (en)
Chinese (zh)
Other versions
CN1189098A (zh
Inventor
�����ɷ�
村松丰二郎
真下克己
筱田泰雄
佐佐博纪
川岛弘行
谷泽良夫
竹内英敦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Nissan Chemical Corp
Original Assignee
Kowa Co Ltd
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Nissan Chemical Corp filed Critical Kowa Co Ltd
Publication of CN1189098A publication Critical patent/CN1189098A/zh
Application granted granted Critical
Publication of CN1137684C publication Critical patent/CN1137684C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB961920653A 1995-12-22 1996-12-20 用碱性试剂稳定的药物组合物 Expired - Lifetime CN1137684C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP35465495 1995-12-22
JP354654/1995 1995-12-22

Publications (2)

Publication Number Publication Date
CN1189098A CN1189098A (zh) 1998-07-29
CN1137684C true CN1137684C (zh) 2004-02-11

Family

ID=18439011

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB961920653A Expired - Lifetime CN1137684C (zh) 1995-12-22 1996-12-20 用碱性试剂稳定的药物组合物

Country Status (26)

Country Link
EP (1) EP0814782B1 (https=)
JP (1) JP3276962B2 (https=)
KR (1) KR100348842B1 (https=)
CN (1) CN1137684C (https=)
AT (1) ATE228354T1 (https=)
AU (1) AU725622B2 (https=)
CA (1) CA2213608C (https=)
CZ (1) CZ288545B6 (https=)
DE (2) DE69625046T2 (https=)
DK (1) DK0814782T3 (https=)
ES (1) ES2183023T3 (https=)
FR (1) FR11C0007I2 (https=)
HU (1) HU227798B1 (https=)
IL (1) IL121565A (https=)
MX (1) MX9706389A (https=)
NO (2) NO316724B1 (https=)
NZ (1) NZ324446A (https=)
PL (1) PL186907B1 (https=)
PT (1) PT814782E (https=)
RU (1) RU2142790C1 (https=)
SI (1) SI0814782T1 (https=)
SK (1) SK282991B6 (https=)
TW (1) TW436294B (https=)
UA (1) UA29513C2 (https=)
WO (1) WO1997023200A1 (https=)
ZA (1) ZA9610792B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
CA2364253A1 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6730418B2 (en) 1999-12-13 2004-05-04 Kabushiki Kaisha Toyota Chuo Kenkyusho Quinoline derivatives and organic electroluminescent devices
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
EP1429802B1 (en) * 2001-09-28 2012-11-07 TNTGamble, Inc. Delivery system for biological component
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AU2003264443A1 (en) * 2002-09-20 2004-04-08 Kowa Co., Ltd. Preparation for external use
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
ATE535614T1 (de) 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
JP4728226B2 (ja) 2004-02-25 2011-07-20 興和株式会社 Ｃｄｃ４２タンパク質の核内移行促進剤及びそのスクリーニング方法
EP1719524B1 (en) 2004-02-25 2014-11-26 Kowa Company, Ltd. Nuclear transfer promoter for rac protein and method of screening the same
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006074265A2 (en) 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP1726962A1 (en) * 2005-05-24 2006-11-29 Leiden University Medical Center Apolipoprotein E plasma levels for monitoring and reducing the risk of cardiovascular disease
EP2170065A4 (en) 2007-06-20 2011-11-23 Merck Sharp & Dohme DIPHENYL SUBSTITUTED ALKANES
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo Prophylactic and/or therapeutic agent against lymphedema
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
US9399064B2 (en) * 2011-04-12 2016-07-26 Sawai Pharmaceutical Co., Ltd. Pitavastatin-containing preparation and method for producing same
EP2697203B1 (en) 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Mineralocorticoid receptor antagonists
WO2012153181A1 (en) 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
CN102861018A (zh) * 2011-07-05 2013-01-09 南京长澳医药科技有限公司 一种匹伐他汀钙制剂及其制备工艺
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
JP5844574B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する安定化された薬物組成物
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US20150164809A1 (en) 2012-08-08 2015-06-18 Kowa Company, Ltd. Medicine
CN102885797A (zh) * 2012-10-29 2013-01-23 福州海王福药制药有限公司 一种含匹伐他汀钙的组合物及其制备方法和应用
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
US10392381B2 (en) 2014-07-18 2019-08-27 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
CN105343008A (zh) * 2015-12-15 2016-02-24 青岛华之草医药科技有限公司 一种匹伐他汀钙组合物
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103983B (zh) * 2006-07-14 2012-09-26 海南盛科生命科学研究院 一种用碱试剂稳定的含匹伐他汀钙的药用组合物及制备工艺

Also Published As

Publication number Publication date
AU1171597A (en) 1997-07-17
FR11C0007I1 (https=) 2011-04-22
IL121565A (en) 2002-02-10
DE69625046D1 (de) 2003-01-09
MX9706389A (es) 1998-08-30
NO973814L (no) 1997-10-13
IL121565A0 (en) 1998-02-08
SI0814782T1 (en) 2003-04-30
ATE228354T1 (de) 2002-12-15
CZ288545B6 (cs) 2001-07-11
NZ324446A (en) 1999-08-30
DK0814782T3 (da) 2002-12-16
FR11C0007I2 (fr) 2012-03-16
CA2213608A1 (en) 1997-07-03
KR19980702370A (ko) 1998-07-15
HUP9903536A3 (en) 2001-06-28
DE122011000014I1 (de) 2011-11-03
EP0814782A1 (en) 1998-01-07
HUP9903536A2 (hu) 2000-03-28
TW436294B (en) 2001-05-28
CN1189098A (zh) 1998-07-29
NO2011006I2 (no) 2012-10-01
JP3276962B2 (ja) 2002-04-22
PL186907B1 (pl) 2004-03-31
ZA9610792B (en) 1997-07-09
SK116097A3 (en) 1998-03-04
WO1997023200A1 (en) 1997-07-03
EP0814782B1 (en) 2002-11-27
DE69625046T2 (de) 2003-04-10
CA2213608C (en) 2003-07-08
HU227798B1 (en) 2012-03-28
JPH11503763A (ja) 1999-03-30
NO973814D0 (no) 1997-08-19
AU725622B2 (en) 2000-10-19
NO2011006I1 (no) 2011-06-06
PL321868A1 (en) 1997-12-22
KR100348842B1 (ko) 2002-12-31
RU2142790C1 (ru) 1999-12-20
SK282991B6 (sk) 2003-01-09
ES2183023T3 (es) 2003-03-16
CZ268197A3 (cs) 1998-05-13
NO316724B1 (no) 2004-04-19
PT814782E (pt) 2003-04-30
UA29513C2 (uk) 2000-11-15

Similar Documents

Publication Publication Date Title
CN1137684C (zh) 用碱性试剂稳定的药物组合物
CN1141097C (zh) 含有稳定化的苯并咪唑类化合物的组合物
CN1642526A (zh) 碱性金属添加剂稳定的阿托伐他汀制剂
CN1041794C (zh) 含有一种β－羟基－β－甲基戊二酸单酰辅酶A还原酶抑制剂的稳定的药物组合物
CN1149993C (zh) 莫西沙星药物制剂
CN1147472C (zh) 具有组蛋白脱乙酰酶抑制剂活性的苯甲酰胺制剂
CN1144598C (zh) 利用氧化镁稳定的含ace抑制剂的组合物
CN101028268A (zh) 药物组合物
EP1944029B1 (en) Pharmaceutical preparation having excellent photostability
CN1197574C (zh) 稳定苯并咪唑化合物的方法
JPWO2005013964A1 (ja) ナテグリニド含有製剤
JPWO2012043709A1 (ja) 難溶性薬物の溶解性改善製剤
CN1253497A (zh) 含扑热息痛的吞咽片剂
CN1214791C (zh) 喹啉酮衍生物药物组合物及其制备方法
CN1219132A (zh) 前列腺素i衍生物缓释制剂
CN1117565C (zh) 西兰塞特隆的抗外消旋的稳定的药物制剂
JP2814513B2 (ja) 溶出性の改良された製剤組成物
CN1636553A (zh) 防挥发型固体制剂及其制造方法
EP0379579A1 (en) Pharmaceutical composition having improved releasability
CN1709253A (zh) 一种含匹伐他汀的稳定的药物组合物
CN1903182A (zh) 小型化盐酸沙格雷酯经口给药制剂
CN1867326A (zh) 加巴喷丁的缓释口服片剂及其制备方法
CN1762354A (zh) 一种含有钙阻滞剂的稳定药物组合物
WO2016088041A1 (en) Extended-release cefpodoxime proxetil composition
CN1765355A (zh) 普罗帕酮缓释制剂及制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20040211

EXPY Termination of patent right or utility model